Gilead Sciences Inc. (NASDAQ: GILD) reported its first-quarter results Thursday after the markets closed. The biotech giant had $2.94 in earnings per share (EPS) on $7.59 billion in revenue, versus Thomson Reuters consensus estimates of $2.32 in EPS on $6.92 billion in revenue. The same quarter from the previous year had $1.48 in EPS on $5.00 billion in revenue.

The company updated its guidance for the full year to a new range of $28 billion to $29 billion in revenue from a prior range of $26 billion to $27 billion. There are consensus estimates of $9.68 in EPS on $28.5 billion in revenue.

Antiviral product sales increased to $7.0 billion for the first quarter of 2015, up from $4.5 billion for the first quarter of 2014 primarily due to sales of Harvoni, which was approved in the United States and Europe in the fourth quarter of 2014, partially offset by a decrease in sales of Sovaldi.

Other product sales, which include Letairis, Ranexa and AmBisome, totaled $417 million for the first quarter, compared to $362 million for the first quarter last year.

In terms of its antiviral product sales, compared to the previous year, Gilead reported:

• Harvoni sales totaled $3.58 billion
• Sovaldi sales totaled $972 million, down from $2.27 billion
• Truvada sales totaled $771 million, up from $760 million
• Atripla sales totaled $734 million, down from $780 million
• Stribild sales totaled $356 million, up from $215 million
• Complera sales totaled $320 million, up from $251 million
• Viread sales totaled $234 million, up from $211 million
• Other antiviral sales totaled $22 million, up from $18 million

As of March 31, 2015, Gilead had $14.5 billion of cash, cash equivalents and marketable securities, compared to $11.7 billion as of December 31, 2014.

ALSO READ: Why These 2 Biotech Stocks May Be Bought Out Soon

Shares of Gilead closed Thursday down 1.8% at $100.52. Following the release of the earnings report, shares were up 3.3% at $103.71 in after-hours trading. So far year to date, Gilead’s stock has rallied 8.6%, with a total market cap of nearly $150 billion. The stock has a consensus analyst price target of $117.99 and a 52-week trading range of $76.63 to $116.83.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.